Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials.
Sarah C RutherfordJun YinLevi D PedersonGabriela Perez BurbanoBetsy LaPlantMazyar ShadmanHongli LiMichael L LeBlancVaishalee P KenkreFangxin HongKristie A BlumTravis DockterPeter MartinSin-Ho JungBarbara GrantCara A RosenbaumChaitra UjjaniPaul M BarrJoseph M UngerBruce D ChesonNancy L BartlettBrad S KahlJonathan W FriedbergSumithra J MandrekarJohn P LeonardPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
We conclude that BMB add little value to response assessment in subjects with FL treated on clinical trials and we recommend eliminating BMB from clinical trial requirements. BMB should also be removed from diagnostic guidelines for FL except in scenarios in which it may change management including confirmation of limited stage and assessment of cytopenias. This would reduce cost, patient discomfort, resource utilization, and potentially remove a barrier to trial enrollment.